ASC618 Gene Therapy in Hemophilia A Patients
Phase 1
Recruiting
- Conditions
- Hemophilia A
- Interventions
- Biological: ASC618
- Registration Number
- NCT04676048
- Lead Sponsor
- ASC Therapeutics
- Brief Summary
Currently, hemophilia A patients are managed with prophylactic or on-demand replacement therapy with recombinant FVIII or alternative therapeutics. The major challenges of current treatment regimens, such as the short half-life of hemophilia therapeutics with the need for frequent IV injections, encourage the current efforts for gene transfer therapy.
This study will evaluate the safety and preliminary efficacy of ASC618, an AAV vector encoding B-domain deleted codon-optimized human factor VIII under a synthetic liver-directed promoter
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
- Male ≥18 years of age
- Severe or moderately severe hemophilia A (FVIII activity ≤ 2 IU/dL) as evidenced by
- medical history
- Received FVIII prophylactic or on-demand replacement therapy for ≥ 150 accumulated
- days (exposure days)
- ≥12 bleeding episodes if receiving on-demand therapy over the preceding 12 months
- BMI ≤ 30
- Agree to use double-barrier contraceptive until at least 3 consecutive semen samples are negative after ASC-618 infusion
Exclusion Criteria
- Pre-existing immunity to AAV8 vector as defined by AAV8 total antibodies and neutralizing antibodies qualified tests.
- Current inhibitors, or history of high titer FVIII inhibitors
- Presence of > Grade 2 liver fibrosis on elastography/Fibroscan or comparable imaging methodology
- History of chronic renal disease
- Active infection or any immunosuppressive disorder
- History of cardiac surgery and need anticoagulant therapy
- Any cardiovascular / genetic risk factors for thromboembolic disorders
- Evidence of active Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV)-1/2 or syphilis infection.
- Receipt of any vector or gene transfer agent
- Current antiviral therapy for hepatitis B or C
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ASC618 ASC618 Experimental Arm
- Primary Outcome Measures
Name Time Method Number of adverse events, and serious AEs 12 months post-infusion
- Secondary Outcome Measures
Name Time Method Changes in FVIII activity levels from baseline 12 months post-infusion Annualized FVIII consumption 12 months post-infusion Annualized bleeding rate (ABR) 12 months post-infusion
Trial Locations
- Locations (1)
Arkansas Children's Hospital
🇺🇸Little Rock, Arkansas, United States